Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share

Fulgent Genetics, Inc.

Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.
GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).
Non-GAAP net income $5.2M ($0.16 per share) in Q4; full-year non-GAAP income $13.2M ($0.42 per share).
Cash, equivalents, restricted cash, and marketable securities totaled $705.5M at year-end, plus $106.3M anticipated tax refund.
Adjusted EBITDA loss of $4.5M in Q4 and $9.4M for full year 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.